Creative Biolabs Announces Upcoming Webinar on Programming Cytokine Sensing for Durable CAR-T Therapies

Creative Biolabs is proud to announce its upcoming webinar, "Programming Cytokine Sensing: A Blueprint for Durable CAR-T", scheduled for December 11, 2025, at 10:00 AM EST. This event will spotlight cutting-edge strategies to overcome one of the most pressing challenges in CAR-T therapy for solid tumors: the dual role of interferon-gamma (IFNγ).

CAR-T therapy has revolutionized the treatment of hematologic malignancies, delivering remarkable clinical outcomes in patients with otherwise refractory disease. Yet, translating this success into solid tumors has proven far more difficult. The tumor microenvironment presents formidable barriers, including immunosuppressive signaling, physical obstacles, and cytokine-mediated feedback loops. Among these, IFNγ stands out as a paradoxical player. While it is essential for activating and sustaining CAR-T effector functions, IFNγ can simultaneously drive T cell exhaustion and limit persistence, particularly when interacting with CD28 co-stimulatory domains. This duality has created a bottleneck in the development of durable CAR-T therapies for solid tumors.

The upcoming Creative Biolabs webinar will address this critical issue head-on. Guest speaker Dr. Stefanie Bailey of the University of Virginia will present her team's latest findings on engineering CAR-T cells to reprogram cytokine sensing. By deleting the IFNγ receptor (IFNγR) in CAR-T cells, her research demonstrates that it is possible to uncouple therapeutic efficacy from exhaustion, thereby extending the persistence and potency of CAR-T therapies in hostile tumor environments. This innovative approach provides a blueprint for designing next-generation CAR-T products that can withstand the complex signaling dynamics of solid tumors.

Key topics to be covered include:

* The dual role of IFNγ in CAR-T therapy and its impact on efficacy and persistence

* Comparative insights into CD28 versus 4-1BB co-stimulatory domains and their cytokine signaling profiles

* Strategies for "subpopulation sensing," tailoring cytokine programming to distinct T cell subsets

* Practical implications for clinical translation and future CAR-T product development

This webinar offers a unique opportunity for researchers, clinicians, and industry professionals to gain actionable insights into overcoming the current limitations of CAR-T therapy. By bridging fundamental immunology with translational engineering, Creative Biolabs aims to empower the scientific community with tools and knowledge to accelerate progress in solid tumor immunotherapy.

Registration is now open, and seats are limited. With CAR-T development at a critical juncture, this event promises to deliver timely, high-impact content that could shape the future of adoptive cell therapy. Don't miss the chance to learn directly from leading experts and explore how cytokine programming can unlock durable responses in solid tumors.

Register today to secure your seat. Join Creative Biolabs and Dr. Bailey on December 11, 2025, to be part of the conversation that is redefining the boundaries of CAR-T innovation.